clinical trial · NCT06159725
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
Clarametyx Biosciences, Inc.·phase2·completed·n = 43
Persistent InfectionCystic FibrosisCMTX-101Placebo
brief summary
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)
started
Jun 24, 2024
primary completion
Nov 14, 2025
completion
Nov 14, 2025
last updated
Nov 21, 2025
official title
A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol